$Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study$

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Pivekimab sunirine (IMGN632) is a first-in-class antibody–drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload. CD123 is overexpressed in several haematological malignancies, including acute myeloid leukaemia. We present cli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2024-03, Vol.25 (3), p.388-399
Hauptverfasser:	Daver, Naval G, Montesinos, Pau, DeAngelo, Daniel J, Wang, Eunice S, Papadantonakis, Nikolaos, Todisco, Elisabetta, Sweet, Kendra L, Pemmaraju, Naveen, Lane, Andrew A, Torres-Miñana, Laura, Thompson, James E, Konopleva, Marina Y, Sloss, Callum M, Watkins, Krystal, Bedse, Gaurav, Du, Yining, Malcolm, Kara E, Zweidler-McKay, Patrick A, Kantarjian, Hagop M
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Adverse events Antibodies CD123 antigen Chemotherapy Clinical trials Dendritic cells Dosage Drug dosages FDA approval Graft versus host disease Granulocytes Hematology Leukemia Malignancy Mutation Neutropenia Patients Remission Remission (Medicine) Response rates Stem cells Tumors Veno-occlusive disease
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!